Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)

Drug Discovery Today: Disease Mechanisms

Volumn 8, Issue 3-4, 2011, Pages

  Peters, Jeffrey M ^a   Morales, Jose L ^a   Gonzalez, Frank J ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLIDINE DERIVATIVE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID;

CANCER PREVENTION; CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM INFLAMMATION; DRUG TARGETING; GENE TARGETING; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 84857643155     PISSN: None     EISSN: 17406765     Source Type: Journal    
DOI: 10.1016/j.ddmec.2011.11.002     Document Type: Review

References (70)

1. Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650
2. Peters, J.M. et al. (2005) Peroxisome proliferator-activated receptor-a and liver cancer: where do we stand? J. Mol. Med. 83, 774-785 (Pubitemid 41407861)
3. Chaggar, P.S. et al. (2009) Review article: thiazolidinediones and heart failure. Diab. Vasc. Dis. Res. 6, 146-152
4. Billin, A.N. (2008) PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert. Opin. Investig. Drugs 17, 1465-1471
5. Berger, J. et al. (1999) Novel peroxisome proliferator-activated receptor (PPAR) g and PPARδ ligands produce distinct biological effects. J. Biol. Chem. 274, 6718-6725 (Pubitemid 29111093)
6. Sznaidman, M.L. et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor d (PPARδ)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13, 1517-1521 (Pubitemid 36428550)
7. Barak, Y. et al. (2002) Effects of peroxisome proliferator-activated receptor d on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 99, 303-308 (Pubitemid 34060358)
8. Gupta, R.A. et al. (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 10, 245-247 (Pubitemid 38667613)
9. Wang, D. et al. (2006) Crosstalk between peroxisome proliferator- activated receptor d and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. U.S.A. 103, 19069-19074 (Pubitemid 350002829)
10. Wang, D. et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferatoractivated receptor d. Cancer Cell 6, 285-295 (Pubitemid 39222041)
11. Zuo, X. et al. (2009) Targeted genetic disruption of peroxisome proliferator-activated receptor-δ and colonic tumorigenesis. J. Natl. Cancer Inst. 101, 762-767
12. Harman, F.S. et al. (2004) Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat. Med. 10, 481-483 (Pubitemid 38667905)
13. Marin, H.E. et al. (2006) Ligand activation of peroxisome proliferatoractivated receptor β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res. 66, 4394-4401
14. Hollingshead, H.E. et al. (2008) Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29, 169-176 (Pubitemid 351201756)
15. He, T.C. et al. (1999) PPARδ is an APC-regulated target of nonsteroidal antiinflammatory drugs. Cell 99, 335-345
16. Girroir, E.E. et al. (2008) Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem. Biophys. Res. Commun. 371, 456-461
17. Berglund, L. et al. (2008) A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol. Cell Proteomics 7, 2019-2027
18. Uhlen, M. et al. (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteomics 4, 1920-1932 (Pubitemid 41830186)
19. Foreman, J.E. et al. (2009) Regulation of peroxisome proliferator- activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol. Carcinog. 48, 942-952
20. Peters, J.M. et al. (2008) Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin. Sci. (Lond.) 115, 107-127
21. Foreman, J.E. et al. (2011) Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer. Mol. Carcinog. 50, 884-900
22. Chen, L.C. et al. (2004) Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res. 64, 3694-3700
23. Burdick, A.D. et al. (2006) The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell Signal 18, 9-20 (Pubitemid 41415710)
24. Peters, J.M. and Gonzalez, F.J. (2009) Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim. Biophys. Acta 1796, 230-241
25. Yang, L. et al. (2011) Biological function and prognostic significance of peroxisome proliferator-activated receptor d in rectal cancer. Clin. Cancer Res. 17, 3760-3770
26. Reed, K.R. et al. (2004) PPARδ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23, 8992-8996 (Pubitemid 39657790)
27. Kilgore, K.S. and Billin, A.N. (2008) PPARβ/δ ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9, 463-469 (Pubitemid 351677899)
28. Alvarez-Guardia, D. et al. (2011) PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochim. Biophys. Acta 1811, 59-67
29. Barroso, E. et al. (2011) The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. Biochem. Pharmacol. 81, 534-543
30. Coll, T. et al. (2010) Activation of peroxisome proliferator-activated receptor-δ by GW501516 prevents fatty acid-induced nuclear factor-kB activation and insulin resistance in skeletal muscle cells. Endocrinology 151, 1560-1569
31. Planavila, A. et al. (2005) Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res. 65, 832-841 (Pubitemid 40249728)
32. Rodriguez-Calvo, R. et al. (2008) Activation of peroxisome proliferatoractivated receptor β/δ (PPARβ/δ) inhibits LPS-induced cytokine production in adipocytes by lowering NF-κB activity via ERK1/2. Diabetes 57, 2149-2157
33. Kino, T. et al. (2007) The PPARδ agonist GW501516 suppresses interleukin- 6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur. J. Clin. Invest. 37, 425-433 (Pubitemid 46653139)
34. Kim, D.J. et al. (2006) PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13, 53-60
35. Dunn, S.E. et al. (2010) Peroxisome proliferator-activated receptor d limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J. Exp. Med. 207, 1599-1608
36. Kanakasabai, S. et al. (2010) Peroxisome proliferator-activated receptor d agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130, 572-588
37. Kanakasabai, S. et al. (2011) PPARδ deficient mice develop elevated Th1/ Th17 responses and prolonged experimental autoimmune encephalomyelitis. Brain Res. 1376, 101-112
38. Mukundan, L. et al. (2009) PPAR-d senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat. Med. 15, 1266-1272
39. Collino, M. et al. (2011) Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. Free Radic. Biol. Med. 50, 345-353
40. Di Paola, R. et al. (2010) GW0742, a high-affinity PPAR-β/δ agonist, inhibits acute lung injury in mice. Shock 33, 426-435
41. Di Paola, R. et al. (2010) GW0742, a selective PPAR-β/δ agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury. J. Leukoc. Biol. 88, 291-301
42. Glatz, T. et al. (2010) Peroxisome-proliferator-activated receptors g and peroxisome-proliferator-activated receptors b/d and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J. Hypertens. 28, 1488-1497
43. Kapoor, A. et al. (2010) Activation of peroxisome proliferator-activated receptor-β/δ attenuates myocardial ischemia/reperfusion injury in the rat. Shock 34, 117-124
44. Kapoor, A. et al. (2010) Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am. J. Respir. Crit. Care Med. 182, 1506-1515
45. Liang, Y.J. et al. (2010) Peroxisome proliferator-activated receptor d agonists attenuated the C-reactive protein-induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts. Eur. J. Pharmacol. 643, 84-92
46. Stockert, J. et al. (2011) Reverse crosstalk of TGFb and PPARβ/δ signaling identified by transcriptional profiling. Nucleic Acids Res. 39, 119-131
47. Zingarelli, B. et al. (2010) Peroxisome proliferator-activated receptor d regulates inflammation via NF-κB signaling in polymicrobial sepsis. Am. J. Pathol. 177, 1834-1847
48. Hollingshead, H.E. et al. (2007) PPARβ/δ protects against experimental colitis through a ligand-independent mechanism. Dig. Dis. Sci. 52, 2912-2919 (Pubitemid 47512523)
49. Lee, J.W. et al. (2007) Fenofibrate represses interleukin-17 and interferongamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 133, 108-123 (Pubitemid 47031123)
50. Di-Poi, N. et al. (2002) Antiapoptotic role of PPARb in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell 10, 721-733
51. Tan, N.S. et al. (2001) Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes Dev. 15, 3263-3277 (Pubitemid 34008192)
52. Roop, D.R. et al. (1987) Regulated expression of differentiation- associated keratins in cultured epidermal cells detected by monospecific antibodies to unique peptides of mouse epidermal keratins. Differentiation 35, 143-150
53. Tyner, A.L. and Fuchs, E. (1986) Evidence for posttranscriptional regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. J. Cell Biol. 103, 1945-1955 (Pubitemid 17189050)
54. Burdick, A.D. et al. (2007) Ligand activation of peroxisome proliferatoractivated receptor-β/δ (PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal. 19, 1163-1171 (Pubitemid 46561554)
55. Borland, M.G. et al. (2008) Ligand activation of peroxisome proliferatoractivated receptor-β/δ (PPARβ/δ) inhibits cell proliferation in human HaCaT keratinocytes. Mol. Pharmacol. 74, 1429-1442
56. Hollingshead, H.E. et al. (2007) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28, 2641-2649 (Pubitemid 350238968)
57. Yang, L. et al. (2008) RNA interference against peroxisome proliferatoractivated receptor d gene promotes proliferation of human colorectal cancer cells. Dis. Colon Rectum 51, 318-328
58. Grimaldi, P.A. (2007) Regulatory functions of PPARb in metabolism: implications for the treatment of metabolic syndrome. Biochim. Biophys. Acta 1771, 983-990 (Pubitemid 47208547)
59. Lee, C.H. et al. (2006) PPARδ regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 103, 3444-3449
60. Takahashi, S. et al. (2007) New therapeutic target for metabolic syndrome: PPARδ. Endocr. J. 54, 347-357 (Pubitemid 47105421)
61. Pais, R. et al. (2009) Metabolic syndrome and risk of subsequent colorectal cancer. World J. Gastroenterol. 15, 5141-5148
62. Prizment, A.E. et al. (2010) Survival of women with colon cancer in relation to precancer anthropometric characteristics: the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev. 19, 2229-2237
63. Terzic, J. et al. (2010) Inflammation and colon cancer. Gastroenterology 138, 2101-2114 e2105
64. Tsugane, S. and Inoue, M. (2010) Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 101, 1073-1079
65. Wolin, K.Y. et al. (2011) Obesity and cancer. Oncologist 15, 556-565
66. Liou, J.Y. et al. (2007) Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3e. Cancer Res. 67, 3185-3191
67. Liou, J.Y. et al. (2006) Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3 upregulation. Arterioscler. Thromb. Vasc. Biol. 26, 1481-1487
68. Liou, J.Y. et al. (2008) Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-δ transcriptional pathway. Mol. Pharmacol. 74, 1399-1406
69. Wu, K.K. and Liou, J.Y. (2009) Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARδ→ 14-3-3e pathway. Methods Mol. Biol. 512, 295-307
70. Shearer, B.G. et al. (2010) Identification and characterization of 4-chloro- N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethylbenzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor d (PPARδ) antagonist. J. Med. Chem. 53, 1857-1861